Health Care·Biotechnology·$3.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | +3.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.74 | N/A | +3.01% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions affecting performance. They reiterated their commitment to long-term objectives without offering specific guidance.
Management highlighted ongoing challenges in the market.
They emphasized the importance of focusing on long-term goals despite short-term setbacks.
There was no specific guidance provided for future quarters.
Denali Therapeutics reported a wider-than-expected loss per share but did not provide revenue figures. The stock fell 3.22% in response to the lack of guidance and management's cautious tone regarding market challenges. Investors may be concerned about the company's ability to navigate these issues moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025